Integer's Tiny Tech to Power Neuromodulation's Next Wave

PLANO, TX – January 14, 2026 – As the global medical technology community prepares to gather in Las Vegas, Integer Holdings Corporation (NYSE: ITGR) is set to take center stage with innovations that promise to reshape the landscape of implantable medical devices. The company announced it will be showcasing its latest advancements in neuromodulation and miniaturized device technology at the North American Neuromodulation Society (NANS) Annual Meeting from January 22-25, 2026, an event themed "From Discovery to Healing."

Integer’s presentation is poised to be a focal point of the conference, highlighting technologies designed not only to push the boundaries of what's possible in patient treatment but also to accelerate how quickly these new therapies can reach the people who need them. The showcase will feature next-generation miniaturized active implantable medical devices (AIMDs) and a revolutionary fast-charging battery system, underscoring a pivotal shift towards smaller, more powerful, and patient-friendly medical solutions.

The Silent Architects of Medical Innovation

While names like Medtronic and Abbott are often in the spotlight, companies like Integer operate as the crucial, often unseen, engine driving the industry forward. As one of the world's largest medical device contract development and manufacturing organizations (CDMO), Integer serves as a strategic partner to the very companies developing cutting-edge therapies. Its role is to provide the foundational components, integrated systems, and manufacturing expertise that turn a novel concept into a market-ready, life-changing product.

This CDMO model is essential for accelerating the pace of innovation. By offering a comprehensive suite of services—from initial design and development to final assembly and sterilization—Integer allows medical device OEMs to de-risk their development process and shorten timelines. Instead of building every component and system from the ground up, innovators can leverage Integer's specialized expertise in critical, high-growth sectors like cardiac rhythm management, neuromodulation, and cardio-vascular devices. This partnership allows them to focus on clinical validation and market strategy, knowing the underlying technology is robust and scalable.

Integer's deep specialization in these complex fields provides a significant competitive advantage. The company's focus isn't just on manufacturing a single part; it's on providing integrated solutions that encompass everything from the power source to the complex lead systems that deliver therapy, ensuring all components work in seamless harmony.

Miniaturization: The Next Frontier in Patient Care

The most significant trend Integer will highlight at NANS is miniaturization, a movement that is fundamentally altering the patient experience. The development of smaller, more compact implantable devices is about far more than just technological novelty; it directly translates to profound benefits in patient care. The global market for active implantable medical devices, valued at over $27 billion in 2025 and projected to exceed $45 billion by 2032, is being driven largely by this push for smaller, less invasive technology.

For patients, the benefits are immediate and tangible. Smaller devices require less invasive surgical procedures, which can lead to reduced trauma, shorter hospital stays, and a lower risk of post-operative complications. A smaller implant is also less obtrusive under the skin, improving long-term comfort and cosmetic outcomes. This shift is expanding access to therapies for patients who, due to anatomical constraints or higher surgical risks, might not have been candidates for older, larger devices.

This evolution is particularly critical in neuromodulation, a field that uses electrical stimulation to treat chronic pain, Parkinson's disease, epilepsy, and a growing list of other conditions. As the neuromodulation market surges towards a projected value of nearly $14 billion by 2033, the demand for more sophisticated and less burdensome devices is paramount. Miniaturization enables the placement of stimulators in new areas of the body and supports the development of more complex, adaptive therapies that can adjust stimulation in real-time for better symptom control.

Powering the Future with a 30-Minute Charge

At the heart of every active implantable device is its power source, a component that has historically presented a major challenge. Limited battery life often meant patients had to undergo repeated surgeries for device replacement. Integer is directly addressing this challenge with its Xcellion® Gen 3 Fast Charge Lithium Ion battery, a key feature of its NANS showcase.

The company touts the technology as offering "best-in-class runtime" and, most impressively, the ability to fully recharge in as little as 30 minutes. This rapid-charging capability represents a monumental leap forward for patient convenience and autonomy. It drastically reduces the time patients must remain tethered to a charging unit, minimizing disruption to their daily lives and improving compliance with treatment regimens. Longer runtimes between charges further enhance this freedom.

This advancement places Integer at the forefront of a critical trend in medical device engineering. The industry is rapidly moving away from non-rechargeable primary cells toward advanced, rechargeable lithium-ion systems that offer higher energy density and longer cycle life. While the future may lie in emerging solid-state batteries or wireless ultrasound charging, Integer's 30-minute recharge sets a new benchmark for current-generation technology, directly impacting the functionality and user-friendliness of the devices it powers.

A Convergence of Innovation at NANS 2026

Integer's showcase at booth #115 arrives at a time when the neuromodulation field is ripe for disruption. The key themes of NANS 2026—including AI-driven neurostimulation, the expansion of therapies beyond pain management, and advanced engineering principles—all depend on the kind of foundational technology Integer provides. More intelligent, adaptive systems require more power and more sophisticated hardware, all within a smaller footprint.

“Miniaturization is transforming the future of implantable technologies, and we’re proud to partner with customers to make that future a reality,” said Jim Stephens, President of Cardiac Rhythm Management & Neuromodulation at Integer. “We invite attendees to visit booth #115 to see how Integer’s expertise – spanning every critical component from high-performance batteries to fully integrated implantable pulse generator and lead systems – can help enable our customers’ innovations.”

By providing these core building blocks, Integer is not just a supplier but an enabler of the next wave of medical breakthroughs. The innovations on display in Las Vegas represent a convergence of engineering, battery science, and manufacturing prowess, all aimed at a single goal: empowering medical device companies to bring novel, more effective, and less invasive therapies to patients worldwide.